VEGF inhibitor bevacizumab has been explored as a therapeutic option for malignant pleural mesothelioma, however the relevant clinical trials of VEGF inhibitors in DMPM are few (19). The gene discussed is VEGFA; the disease is malignant pleural mesothelioma.